Search results for "Psoriatic Arthriti"
showing 10 items of 61 documents
Cardiovascular risk in psoriatic arthritis, a narrative review
2020
Abstract Introduction Psoriatic arthritis (PsA) is a chronic inflammatory rheumatism characterized for a long time by a high degree of cardiovascular risk. Chronic inflammation is one of the mechanisms that explain this cardiovascular excess of risk through direct and indirect pathways. In recent years, epidemiological data have changed somewhat since the increasing use of bio-drugs that are effective in reducing this inflammation. The purpose of this review is to assess the current state of cardiovascular morbidity and mortality in PsA and thus to assess the cardiovascular risk in case of PsA. Method We conducted a literature review using Pubmed and Medline databases with the following key…
S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 1.
2019
The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology, pediatrics, pediatric dermatology and pediatric rheumatology as well as policymakers and insurance funds. They were developed by dermatologists and pediatric dermatologists in collaboration with pediatric rheumatologists using a formal consensus process (S2k). The guidelines highlight topics such as disease severity, quality of life, treatment goals as well as problems associated with off-label drug therapy in children. Trigger factors and diagnostic aspects are discussed. The primary focus is on the various topical, systemic and UV-based treatment options available and includes recomm…
SAT0385 Lack of Correlation between Clinical and Ultrasonographic Evidence of Disease Activity in Psoriatic Arthritis:
2014
Background Musculoskeletal ultrasound (US) has been shown to be a sensitive tool to detect inflammation in inflammatory arthritides [1]. In practice, the composite clinical metric DAS28 is used as a feasible tool for measurement of disease activity, not only in rheumatoid arthritis but also for peripheral arthritis in psoriatic arthritis (PsA). Although both types of measures may reflect disease activity in inflammatory arthritis, some data have shown a poor correlation between clinical and US findings [2]. Objectives To compare clinical and US assessments of active disease in PsA patients. Methods In this cross sectional study PsA patients were consecutively recruited from an outpatient cl…
Burned to the Bone
2017
A burn-related injury that had worsened over time was compatible upon radioclinical examination with severe psoriatic arthritis (PsA), but was missing several essential characteristics of that disorder. A 58-year-old woman with no personal or family history of rheumatic diseases consulted for hand arthralgia. Her medical history was marked by severe burns to 80% of her body, sparing the face and the back, following a gas explosion 20 years earlier. …
Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritis
2017
Assessment of etanercept efficacy in the treatment of psoriatic arthritis: ultrasonography of Achilles tendon
2015
Anti-Tumour Necrosis Factor-?? Therapy for Rheumatoid and Other Inflammatory Arthropathies
2006
Anti-tumour necrosis factor (TNF)-alpha represents a major advance in the treatment of rheumatoid arthritis (RA), ankylosing spondylitis and psoriatic arthritis. It is usually well tolerated, but a potential increase in the incidence of some infections in patients taking anti-TNFalpha agents has been reported. Compared with younger people, elderly patients have more co-morbidities and are likely to be taking more medications. Moreover, the aging process induces an increase in the rate of infections. Nevertheless, in recent studies analysing the databases of etanercept trials, the normalised incidence of adverse events, serious adverse events, medically important infections and deaths was no…
AB1232 RHEUMA-VOR: A PROOF-OF-CONCEPT NETWORK STUDY FOR THE IMPROVEMENT OF RHEUMATOLOGICAL HEALTH CARE THROUGH COORDINATED COOPERATION
2019
Background Rheumatoid arthritis (RA), psoriasis arthritis (PsA) and spondyloarthritis (SpA) are the most common chronic autoimmune rheumatic diseases. For all 3, the so-called “window of opportunity” [1-3] has been identified as the decisive factor affecting the outcome. Objectives The aim of the prospective study is to improve early diagnosis of RA, PsA and SpA and thus positively impact the quality of care for patients with the help of coordinating centers. The primary endpoint is the number of cases with an actual indication for immediate referral to a specialist in proportion to all reported cases. Methods The project establishes a network of the University Medical Center Mainz, the Med…
SAT0132 DOES JANUS KINASE INHIBITION INDUCED HYPERLIPIDAEMIA ASSOCIATE WITH AN INCREASE OF AORTIC STIFFNESS IN PATIENTS WITH ARTHRITIS? PRELIMINARY R…
2020
Background:Treatment with Janus Kinase inhibitors (JAK-i) (Tofacitinib, Baricitinib) can cause an increase of serum lipids such as total cholesterol, low- (LDL) and high- (HDL) density lipoproteins in patients with arthritis (1). On the other hand, JAK-i can reduce systemic inflammation and have therefore a beneficial effect on the cardiovascular system of treated patients. However, the effects of JAK-i on the CV system have not been adequately examined. In particular, we are not aware of any ’’real world’’ data concerning CV risk of patients receiving JAK-i treatment.Stiffness of the aortic vasculature is a modifiable, valid and independent surrogate predictor of CV risk and can be measure…
S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 2.
2019
The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology, pediatrics, pediatric dermatology and pediatric rheumatology as well as policymakers and insurance funds. They were developed by dermatologists and pediatric dermatologists in collaboration with pediatric rheumatologists using a formal consensus process (S2k). The guidelines highlight topics such as disease severity, quality of life, treatment goals as well as problems associated with off-label drug therapy in children. Trigger factors and diagnostic aspects are discussed. The primary focus is on the various topical, systemic and UV-based treatment options available and includes recomm…